Australia's federal health department has warned healthcare professionals to tread carefully with AI-powered medical scribing tools, citing data privacy risks, a lack of patient consent standards, and the potential for clinical errors, as the country's drugs and device regulator weighs whether to classify the tools as medical devices. The caution, reported by The Guardian Australia, comes as use of the scribes among doctors has nearly doubled in just over a year, testing the limits of an oversight system designed for a pre-AI era.
Adoption doubles as workers seek relief from paperwork
An online survey by the Royal Australian College of General Practitioners found that 40 percent of doctors were using AI scribes by November 2025, up from 22 percent in August 2024. The tools record, transcribe, and summarise conversations between clinicians and patients, producing clinical notes that reduce the administrative burden on healthcare workers. Technology providers say their platforms have processed hundreds of millions of consultations globally over the past 18 months.
Privacy and consent gaps draw scrutiny
The health department's briefing papers, prepared for Senate Estimates in February 2026, describe a technology with "little oversight" and note that some AI scribes are marketed as operating outside medical device regulations despite use in clinical settings. Officials found that some companies promote their products as privacy compliant but provide scant transparency about where and how patient data is processed. In some cases, healthcare providers may not even realise patient data is being transmitted to cloud servers outside Australia.
Patient consent practices vary widely. The government argues that meaningful informed consent requires patients to understand both the benefits and limits of AI-assisted documentation. Consumer groups have reported instances where patients were told they would need to find another healthcare provider if they refused to let an AI scribe record their appointment.
A fractured regulatory landscape and the medical device question
Oversight is split among the Therapeutic Goods Administration (TGA), the Australian Health Practitioner Regulation Agency, and the Office of the Australian Information Commissioner. The TGA is now reviewing whether AI scribes should be formally classified as medical devices. A decision to bring these platforms under stricter scrutiny could have wide-reaching implications for how the tools are marketed and used. The TGA report is expected in the coming months. The TGA review is part of a broader push by government agencies to get a handle on AI risks before they outstrip existing safeguards.
Policy makers wrestling with how to classify AI tools and protect patient data face difficult decisions that demand a working knowledge of the technology. The health department also questioned marketing claims that AI scribes can increase a doctor's revenue by about 30 percent without longer hours or more patients. Officials warned that such incentives could drive higher billing, with consequences for the publicly funded Medicare system.
Why this matters for government professionals
For public servants working in health regulation, digital policy, or procurement, the AI scribe debate underscores a pattern that will repeat across many technologies: adoption will sprint ahead of the rules. The TGA's pending classification decision is a case study in how legacy frameworks must adapt to software that can directly shape clinical records and influence patient care. Officials in other agencies will need to track the outcome because it may set a precedent for other AI tools now entering government services. Understanding the technology's mechanics, its failure modes, and its data flows is no longer optional for anyone writing the rules that govern its use.
Your membership also unlocks:
